Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments

Link to article at PubMed

Clin Microbiol Infect. 2023 Sep 2:S1198-743X(23)00412-3. doi: 10.1016/j.cmi.2023.08.028. Online ahead of print.


BACKGROUND: Respiratory syncytial virus (RSV) is widely known as a frequent cause of respiratory distress among adults, particularly older people. Recent years have witnessed several improvements in respiratory virus detection, leading to more questions about therapeutic management strategies.

OBJECTIVES: This narrative review focuses on the RSV burden in older people and adults with risk factors and provides an update on the main recent developments regarding managing this infection.

METHODS: A comprehensive PubMed search was conducted till mid-August 2023 to identify studies on RSV among the adult population. We included observational studies, RCTs on vaccines, and different therapies.

IMPLICATIONS: This review aims to provide clinicians with an overview of RSV epidemiology and burden among older people and adults with pre-existing risk factors, the most recent randomized clinical trials of RSV vaccines, and the existing data on the different therapeutics available and under development.

PMID:37666450 | DOI:10.1016/j.cmi.2023.08.028

Leave a Reply

Your email address will not be published. Required fields are marked *